景峰医药(000908) - 2018 Q1 - 季度财报

Financial Performance - The company's operating revenue for the first quarter of 2018 was ¥382,981,405.89, representing an increase of 8.39% compared to ¥353,350,569.11 in the same period last year[6]. - Net profit attributable to shareholders decreased by 54.40% to ¥15,134,422.93 from ¥33,191,756.06 year-on-year[6]. - The net profit after deducting non-recurring gains and losses fell by 79.64% to ¥5,879,308.61 compared to ¥28,875,637.67 in the previous year[6]. - Basic and diluted earnings per share decreased by 54.38% to ¥0.0172 from ¥0.0377 year-on-year[6]. - The net profit attributable to shareholders decreased by 54.40% to ¥15,134,422.93, influenced by increased R&D spending and ongoing investments in new hospitals[14]. Cash Flow - The net cash flow from operating activities improved significantly, reaching ¥107,677,380.92, a 136.08% increase from a negative cash flow of ¥298,422,480.34 in the same period last year[6]. - Net cash flow from operating activities improved by 136.08% to ¥107,677,380.92, mainly due to the maturity of bank acceptance bills[17]. - The net cash flow from financing activities decreased by 4081.95% to -¥242,149,454.99, due to the repurchase of private bonds and repayment of bank loans[17]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,602,609,797.63, down 5.47% from ¥4,868,764,276.66 at the end of the previous year[6]. - The net assets attributable to shareholders increased by 0.86% to ¥2,398,944,552.21 from ¥2,378,469,144.10 at the end of the previous year[6]. - Total cash and cash equivalents decreased by 40.24% to ¥282,120,327.12, primarily due to the repurchase of ¥200 million in private bonds[15]. - Other receivables increased by 1574.64% to ¥313,326,422.05, mainly due to an increase in business promotion reserves[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,458[10]. - The largest shareholder, Ye Xiangwu, holds 19.80% of the shares, amounting to 174,166,182 shares, with 163,737,882 shares pledged[10]. Expenses - Management expenses increased by 79.25% to ¥82,986,727.32 due to increased R&D investments by Sungen Pharma, LLC and depreciation from new assets at Yunnan Liandong Orthopedic Hospital[14]. - Financial expenses rose by 94.48% to ¥25,745,254.78 primarily due to increased interest from loans and bond issuance[14]. Investment Activities - Investment income surged by 541.31% to ¥2,721,380.40, attributed to a net gain of ¥6.16 million from the disposal of equity in Haimen Haihui Pharmaceutical Technology Co., Ltd.[14]. - The company completed the sale of a 69.0094% stake in Haimen Haihui Pharmaceutical Technology Co., Ltd. for ¥31.65 million, enhancing resource integration[18]. - The company’s shareholding in Jiangze Biotechnology was diluted from 39.98% to 33.98% after a convertible loan was fully converted into equity[18].